To address the translational gap in converting continuous glucose monitoring (CGM) metrics into actionable therapeutic responses for diabetes management, specifically focusing on the lack of algorithms for stage-specific interventions.
Key Findings:
The proposed three-stage model of type 2 diabetes emphasizes β-cell function decline and glycaemic trajectory, providing a clearer framework for patient management.
TITR (time in tight range) is introduced as a key metric for disease staging, highlighting its importance in clinical decision-making.
Current clinical guidelines lack actionable algorithms for translating CGM data into therapeutic actions, underscoring the need for the proposed model.
Interpretation:
The model aims to enhance diabetes management by prioritizing glycaemic stability and providing structured frameworks for lifestyle and pharmacotherapy coordination, ultimately improving patient outcomes.
Limitations:
Provisional nature of TITR thresholds and the risk of overtreatment, which may complicate clinical decision-making.
Implementation barriers that may hinder real-world adoption of the proposed model, potentially affecting patient care.
Conclusion:
Bridging the CGM decision gap requires prospective validation of stage-specific targets and integration of decision-support tools into electronic health records, which could transform diabetes management.
